

Pertti Jaakko Neuvonen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8919721/publications.pdf>

Version: 2024-02-01

334
papers

24,374
citations

5268

83
h-index

11308

136
g-index

337
all docs

337
docs citations

337
times ranked

11247
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 565-581.	4.7	705
2	Pharmacokinetic Interactions with Rifampicin. <i>Clinical Pharmacokinetics</i> , 2003, 42, 819-850.	3.5	591
3	Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. <i>Pharmacological Reviews</i> , 2011, 63, 157-181.	16.0	546
4	SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 873-879.	1.5	425
5	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). <i>Pharmacogenetics and Genomics</i> , 2004, 14, 429-440.	5.7	391
6	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 332-341.	4.7	389
7	Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 481-485.	4.7	386
8	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 468-478.	4.7	320
9	A potentially hazardous interaction between erythromycin and midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 298-305.	4.7	313
10	Gemfibrozil greatly increases plasma concentrations of cerivastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 685-691.	4.7	296
11	Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 601-607.	4.7	287
12	Grapefruit juiceâ€™s simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 477-483.	4.7	283
13	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. <i>Diabetologia</i> , 2003, 46, 347-351.	6.3	269
14	Effect of itraconazole on the pharmacokinetics of atorvastatin*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 58-65.	4.7	267
15	Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 177-182.	4.7	267
16	Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 54-61.	4.7	254
17	Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 397-402.	4.7	250
18	The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 53-58.	1.9	246

#	ARTICLE	IF	CITATIONS
19	Plasma concentrations of active simvastatin acid are increased by gemfibrozil. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 122-129.	4.7	235
20	Rifampin drastically reduces plasma concentrations and effects of oral midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 7-13.	4.7	219
21	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 356-366.	4.7	215
22	The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam. <i>Anesthesia and Analgesia</i> , 1996, 82, 511-516.	2.2	187
23	Cyclosporine markedly raises the plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 388-399.	4.7	180
24	Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy. <i>Obstetrics and Gynecology</i> , 2005, 106, 1289-1296.	2.4	180
25	Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. <i>Clinical Pharmacokinetics</i> , 2008, 47, 463-474.	3.5	177
26	Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 118-127.	4.7	175
27	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. <i>Pharmacological Reviews</i> , 2016, 68, 168-241.	16.0	175
28	Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 340-345.	4.7	174
29	Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1352-1356.	3.3	174
30	Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 326-332.	4.7	172
31	Different effects of the <i>ABCG2</i> c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. <i>Pharmacogenomics</i> , 2009, 10, 1617-1624.	1.3	171
32	Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 538-544.	4.7	170
33	Itraconazole Decreases Renal Clearance of Digoxin. <i>Therapeutic Drug Monitoring</i> , 1997, 19, 609-613.	2.0	169
34	Global analysis of genetic variation in <i>SLCO1B1</i> . <i>Pharmacogenomics</i> , 2008, 9, 19-33.	1.3	168
35	Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. <i>Diabetologia</i> , 2003, 46, 1319-1323.	6.3	167
36	Dose of midazolam should be reduced during diltiazem and verapamil treatments.. <i>British Journal of Clinical Pharmacology</i> , 1994, 37, 221-225.	2.4	164

#	ARTICLE	IF	CITATIONS
37	Clinical Pharmacokinetics of Oral Activated Charcoal in Acute Intoxications. <i>Clinical Pharmacokinetics</i> , 1982, 7, 465-489.	3.5	159
38	Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 384-390.	4.7	154
39	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 380-387.	4.7	154
40	Oral Activated Charcoal in the Treatment of Intoxications. <i>Medical Toxicology</i> , 1988, 3, 33-58.	1.7	151
41	Metabolism of Repaglinide by CYP2C8 and CYP3A4 <i>in vitro</i> : Effect of Fibrates and Rifampicin. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 97, 249-256.	2.5	149
42	Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 348-354.	4.7	147
43	Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. <i>European Journal of Clinical Pharmacology</i> , 2002, 57, 799-804.	1.9	143
44	Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 56-60.	2.4	142
45	Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively. <i>Drug Metabolism and Disposition</i> , 2002, 30, 631-635.	3.3	141
46	Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 127-131.	4.7	138
47	Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin. <i>Epilepsia</i> , 1996, 37, 253-257.	5.1	133
48	The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 770-775.	2.3	133
49	Itraconazole greatly increases plasma concentrations and effects of felodipine. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 410-415.	4.7	132
50	Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 592-597.	4.7	132
51	Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 154-167.	4.7	132
52	In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 547-553.	2.4	131
53	Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 598-606.	4.7	130
54	Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 192-198.	4.7	126

#	ARTICLE	IF	CITATIONS
55	The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam. <i>Anesthesia and Analgesia</i> , 1996, 82, 511-516.	2.2	124
56	Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 498-507.	4.7	124
57	Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro: Potential for Interactions with CYP2C8 Inhibitors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 44-51.	2.5	123
58	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 382-387.	1.5	122
59	Grapefruit juice substantially increases plasma concentrations of buspirone*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 655-660.	4.7	119
60	Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 362-370.	4.7	116
61	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 303-309.	1.5	112
62	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 225-229.	1.9	111
63	Interference of dairy products with the absorption of ciprofloxacin. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 498-502.	4.7	110
64	Trimethoprim and the CYP2C8 ³ Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone. <i>Drug Metabolism and Disposition</i> , 2008, 36, 73-80.	3.3	110
65	Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 409-415.	1.9	106
66	The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 487-494.	4.7	105
67	Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 400-406.	4.7	104
68	Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 363-368.	4.7	103
69	Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 33-39.	4.7	103
70	Differential Inhibition of Cytochrome P450 3A4, 3A5 and 3A7 by Five Human Immunodeficiency Virus (HIV) Protease Inhibitors in vitro. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 79-85.	2.5	100
71	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 404-414.	4.7	99
72	Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 331-341.	4.7	98

#	ARTICLE	IF	CITATIONS
73	Triazolam is ineffective in patients taking rifampin. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 8-14.	4.7	96
74	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 801-808.	1.5	96
75	Itraconazole increases plasma concentrations of quinidine*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 510-517.	4.7	92
76	Orange juice substantially reduces the bioavailability of the β_2 -adrenergic blocking agent celiprolol. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 184-190.	4.7	92
77	Rifampin decreases the plasma concentrations and effects of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 495-500.	4.7	91
78	High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 51-60.	2.3	90
79	Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone. <i>Anesthesiology</i> , 2009, 110, 1371-1378.	2.5	90
80	The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 58-65.	4.7	88
81	Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. <i>Journal of Pediatrics</i> , 2000, 136, 767-770.	1.8	87
82	Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 400-411.	4.7	87
83	Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 411-415.	1.9	85
84	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 312-322.	8.7	85
85	Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 1995, 40, 270-272.	2.4	84
86	Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 349-353.	2.4	84
87	Effects of Daily Ingestion of Cranberry Juice on the Pharmacokinetics of Warfarin, Tizanidine, and Midazolam—Probes of CYP2C9, CYP1A2, and CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 833-839.	4.7	84
88	Different Effects of <i>SLCO1B1</i> Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 311-321.	2.0	83
89	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 441-447.	2.4	81
90	Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 101-109.	4.7	81

#	ARTICLE	IF	CITATIONS
91	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 239-249.	4.7	80
92	Intravenous Lipid Emulsion Sequesters Amiodarone in Plasma and Eliminates Its Hypotensive Action in Pigs. <i>Annals of Emergency Medicine</i> , 2010, 56, 402-408.e2.	0.6	80
93	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 718-726.	2.4	80
94	Acetaminophen Improves Analgesia but Does Not Reduce Opioid Requirement After Major Spine Surgery in Children and Adolescents. <i>Spine</i> , 2012, 37, E1225-E1231.	2.0	80
95	Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 463-472.	1.9	79
96	The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 403-411.	4.7	79
97	Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 25-30.	1.9	77
98	Effect of rifampicin on the pharmacokinetics of pioglitazone. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 70-78.	2.4	75
99	Voriconazole drastically increases exposure to oral oxycodone. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 263-271.	1.9	75
100	Inhibition of Terfenadine Metabolism. <i>Clinical Pharmacokinetics</i> , 1994, 27, 1-5.	3.5	74
101	Prescription drugs during pregnancy and lactation – a Finnish register-based study. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 127-133.	1.9	74
102	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. <i>British Journal of Pharmacology</i> , 2012, 165, 2787-2798.	5.4	74
103	Diltiazem enhances the effects of triazolam by inhibiting its metabolism*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 369-375.	4.7	72
104	Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 488-496.	4.7	71
105	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 77-90.	1.5	71
106	Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 650-658.	4.7	70
107	Donor Simvastatin Treatment Abolishes Rat Cardiac Allograft Ischemia/Reperfusion Injury and Chronic Rejection Through Microvascular Protection. <i>Circulation</i> , 2011, 124, 1138-1150.	1.6	69
108	Effect of Diltiazem on Midazolam and Alfentanil Disposition in Patients Undergoing Coronary Artery Bypass Grafting. <i>Anesthesiology</i> , 1996, 85, 1246-1252..	2.5	68

#	ARTICLE	IF	CITATIONS
109	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 78-87.	2.4	67
110	Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 181-187.	2.4	66
111	Dose-dependent Inhibition of Platelet Function by Acetaminophen in Healthy Volunteers. <i>Anesthesiology</i> , 2005, 103, 712-717.	2.5	66
112	Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 732-740.	2.4	66
113	Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1- α -hydroxylation. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 333-337.	2.4	65
114	Long-term persistence with statin therapy: A nationwide register study in Finland. <i>Clinical Therapeutics</i> , 2008, 30, 2228-2240.	2.5	65
115	Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 640-645.	4.7	64
116	Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 68-71.	4.7	64
117	Methylprednisolone in Neonatal Cardiac Surgery: Reduced Inflammation Without Improved Clinical Outcome. <i>Annals of Thoracic Surgery</i> , 2013, 95, 2126-2132.	1.3	64
118	Pharmacokinetics of Intravenous Paracetamol in Elderly Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 121-129.	3.5	63
119	Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 323-32.	2.3	63
120	Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 33, 386-393.	4.7	62
121	Rifampin reduces plasma concentrations and effects of zolpidem*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 629-634.	4.7	62
122	Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 362-369.	4.7	62
123	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 345-357.	2.4	62
124	The effect of <i>SLCO1B1</i> polymorphism on repaglinide pharmacokinetics persists over a wide dose range. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 818-825.	2.4	62
125	Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 387-397.	1.9	61
126	Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 319-323.	2.4	60

#	ARTICLE	IF	CITATIONS
127	Morphine clearance and effects in newborn infants in relation to gestational age. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 160-166.	4.7	60
128	Bioavailability of Phenytoin. <i>Clinical Pharmacokinetics</i> , 1979, 4, 91-103.	3.5	59
129	Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 448-453.	4.7	59
130	Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of gimepiride. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 194-200.	4.7	59
131	Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 451-461.	1.9	59
132	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. <i>Pharmacogenomics Journal</i> , 2008, 8, 268-277.	2.0	59
133	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 937-942.	1.5	59
134	St John's wort greatly reduces the concentrations of oral oxycodone. <i>European Journal of Pain</i> , 2010, 14, 854-859.	2.8	59
135	Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 465-470.	2.4	58
136	Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 977-985.	1.9	58
137	Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1977-1986.	3.3	58
138	Tolfenamic Acid, Metoclopramide, Caffeine and Their Combinations in The Treatment of Migraine Attacks. <i>Cephalalgia</i> , 1984, 4, 253-263.	3.9	57
139	Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response. <i>Drug Metabolism and Disposition</i> , 2013, 41, 50-59.	3.3	57
140	Midazolam β -Hydroxylation by Human Liver Microsomes <i>in vitro</i> : Inhibition by Calcium Channel Blockers, Itraconazole and Ketoconazole. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 157-161.	0.0	56
141	Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 137-141.	1.9	56
142	Effects of grapefruit juice on the absorption of levothyroxine. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 337-341.	2.4	56
143	Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 447-457.	1.5	56
144	In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1202-1209.	3.3	56

#	ARTICLE	IF	CITATIONS
145	Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 223-230.	4.7	54
146	Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 359-367.	2.0	54
147	Itraconazole Decreases the Clearance and Enhances the Effects of Intravenously Administered Methylprednisolone in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 29-32.	0.0	53
148	The effect of ingestion time interval on the interaction between itraconazole and triazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 326-331.	4.7	52
149	No significant effect of <i>SLCO1B1</i> polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 78-86.	2.4	52
150	No significant effect of <i>ABCB1</i> haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 207-213.	2.4	52
151	A Randomized Clinical Trial of Histamine 2 Receptor Antagonism in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 472-478.	1.4	52
152	Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the <i>SLCO1B1</i> and <i>ABCB1</i> genes. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 706-715.	2.4	51
153	Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 219-228.	4.7	51
154	Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 589-593.	4.7	50
155	Prescription of Hazardous Drugs During Pregnancy. <i>Drug Safety</i> , 2004, 27, 899-908.	3.2	50
156	Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 579-586.	4.7	50
157	Itraconazole Increases Serum Digoxin Concentration. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 79, 274-276.	0.0	49
158	Identification of Drugs Ingested in Acute Poisoning: Correlation of Patient History With Drug Analyses. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 749-752.	2.0	49
159	CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2359-2366.	3.3	49
160	Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 307-313.	4.7	49
161	Grapefruit Juice Enhances the Exposure to Oral Oxycodone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 782-788.	2.5	48
162	Effects of the Antifungals Voriconazole and Fluconazole on the Pharmacokinetics of S-(+)- and R-(-)-Ibuprofen. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1967-1972.	3.2	47

#	ARTICLE	IF	CITATIONS
163	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 591-595.	2.4	46
164	Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone. <i>Clinical Drug Investigation</i> , 2011, 31, 143-153.	2.2	46
165	Itraconazole interacts with felodipine. <i>Journal of the American Academy of Dermatology</i> , 1995, 33, 134-135.	1.2	45
166	The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil. <i>Anesthesia and Analgesia</i> , 1998, 87, 190-194.	2.2	45
167	Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 215-221.	4.7	45
168	Effect of Ethanol and pH on the Adsorption of Drugs to Activated Charcoal: Studies <i>in Vitro</i> and in Man. <i>Acta Pharmacologica Et Toxicologica</i> , 1984, 54, 1-7.	0.0	45
169	Intravenous Lipid Emulsion Entraps Amitriptyline into Plasma and Can Lower its Brain Concentration – An Experimental Intoxication Study in Pigs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 193-200.	2.5	45
170	Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 231-242.	4.7	44
171	Voriconazole and fluconazole increase the exposure to oral diazepam. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 941-949.	1.9	43
172	Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 648-654.	4.7	42
173	Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 382-390.	4.7	42
174	Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 17-24.	1.9	42
175	Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral Ketamine. <i>European Journal of Pain</i> , 2010, 14, 625-629.	2.8	42
176	Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations. <i>Drug Metabolism and Disposition</i> , 2011, 39, 904-911.	3.3	42
177	Rifampicin has a Profound Effect on the Pharmacokinetics of Oral Ketamine and Less on Intravenous Ketamine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 325-332.	2.5	42
178	A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2020, 59, 781-808.	3.5	42
179	Enhancement of Drug Absorption by Antacids. <i>Clinical Pharmacokinetics</i> , 1994, 27, 120-128.	3.5	41
180	<i>In vitro</i> Inhibition of CYP1A2 by Model Inhibitors, Anti-inflammatory Analgesics and Female Sex Steroids: Predictability of <i>in vivo</i> Interactions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 157-165.	2.5	41

#	ARTICLE	IF	CITATIONS
181	Elimination of Intravenous Oxycodone in the Elderly. <i>Drugs and Aging</i> , 2011, 28, 41-50.	2.7	41
182	Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. <i>In Silico Pharmacology</i> , 2013, 1, 6.	3.3	41
183	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 427-432.	2.4	40
184	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 433-439.	2.4	40
185	Determination of Oxycodone, Noroxycodone, Oxymorphone, and Noroxymorphone in Human Plasma by Liquid Chromatography-Electrospray-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 333-340.	2.0	40
186	CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 257-267.	2.4	39
187	Effects of grapefruit juice on the pharmacokinetics of acebutolol. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 659-663.	2.4	38
188	Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 465-470.	2.4	38
189	The Effect of Dexamethasone on the Pharmacokinetics of Triazolam. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1998, 83, 135-138.	0.0	37
190	Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 37-42.	1.9	37
191	Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2006, 34, 2091-2096.	3.3	37
192	Gender, but not <i>CYP7A1</i> or <i>SLCO1B1</i> Polymorphism, Affects the Fasting Plasma Concentrations of Bile Acids in Human Beings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 245-252.	2.5	37
193	Activated Charcoal and Syrup of Ipecac in Prevention of Cimetidine and Pindolol Absorption in man after Administration of Metoclopramide as an Antiemetic Agent. <i>Journal of Toxicology: Clinical Toxicology</i> , 1984, 22, 103-114.	1.5	36
194	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 377-381.	4.7	36
195	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 208-217.	2.4	36
196	<i>SLCO2B1</i> c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 19-24.	1.5	36
197	Acute Dapsone Intoxication: A Case with Prolonged Symptoms. <i>Clinical Toxicology</i> , 1979, 14, 79-85.	0.5	35
198	Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 390-396.	2.4	35

#	ARTICLE	IF	CITATIONS
199	Effect of carboxylesterase 1 c.428G>>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1131-1138.	2.4	35
200	A prospective study of acute poisonings in Finnish hospital patients. <i>Human and Experimental Toxicology</i> , 1998, 17, 307-311.	2.2	34
201	Comparison of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins) as Inhibitors of Cytochrome P450 2C8. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 97, 104-108.	2.5	34
202	Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 463-469.	1.9	34
203	<i>SLCO1B1</i> Polymorphism and Oral Antidiabetic Drugs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 775-781.	2.5	34
204	Interactions of Buspirone with Itraconazole and Rifampicin: Effects on the Pharmacokinetics of the Active 1-(2-Pyrrolidinyl)piperazine Metabolite of Buspirone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 84, 94-97.	0.0	33
205	Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam*1. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 401-407.	4.7	33
206	Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 178-185.	4.7	33
207	Inhibition of Cytochrome P450 3A by Clarithromycin Uniformly Affects the Pharmacokinetics and Pharmacodynamics of Oxycodone in Young and Elderly Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 302-308.	1.4	33
208	A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450A by Voriconazole. <i>Clinical Pharmacokinetics</i> , 2013, 52, 763-781.	3.5	33
209	Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 975-985.	2.4	33
210	The clinical significance of food-drug interactions: a review. <i>Medical Journal of Australia</i> , 1989, 150, 36-40.	1.7	32
211	The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil. <i>Anesthesia and Analgesia</i> , 1998, 87, 190-194.	2.2	32
212	Fluvoxamine is a More Potent Inhibitor of Lidocaine Metabolism than Ketoconazole and Erythromycin <i>in vitro</i> . <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 201-205.	0.0	32
213	Out-of-hospital administration of activated charcoal by emergency medical services. <i>Annals of Emergency Medicine</i> , 2005, 45, 207-212.	0.6	32
214	The Effect of Erythromycin and Fluvoxamine on the Pharmacokinetics of Intravenous Lidocaine. <i>Anesthesia and Analgesia</i> , 2005, 100, 1352-1356.	2.2	32
215	Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 502-508.	4.7	32
216	Pioglitazone, an <i>in vitro</i> inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 217-223.	1.9	32

#	ARTICLE	IF	CITATIONS
217	Statins and Hip Fracture Prevention – A Population Based Cohort Study in Women. PLoS ONE, 2012, 7, e48095.	2.5	32
218	Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. British Journal of Clinical Pharmacology, 2013, 75, 1488-1496.	2.4	32
219	Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. European Journal of Clinical Pharmacology, 2014, 70, 319-329.	1.9	32
220	Effect of Erythromycin and Itraconazole on the Pharmacokinetics of Oral Lignocaine. Basic and Clinical Pharmacology and Toxicology, 1999, 84, 143-146.	0.0	31
221	Effect of Telithromycin on the Pharmacokinetics and Pharmacodynamics of Oral Oxycodone. Journal of Clinical Pharmacology, 2010, 50, 101-108.	2.0	31
222	St John's wort greatly decreases the plasma concentrations of oral ketamine. Fundamental and Clinical Pharmacology, 2012, 26, 743-750.	1.9	31
223	Methylprednisolone Exposure, Rather than Dose, Predicts Adrenal Suppression and Growth Inhibition in Children with Liver and Renal Transplants. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 75-77.	3.6	30
224	Drug-Related Visits to a District Hospital Emergency Room. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 212-217.	2.5	30
225	Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. European Journal of Clinical Pharmacology, 2006, 62, 503-509.	1.9	30
226	Shift of statin use towards the elderly in 1995~2005: a nationwide register study in Finland. British Journal of Clinical Pharmacology, 2008, 66, 405-410.	2.4	30
227	Miconazole Oral Gel Increases Exposure to Oral Oxycodone by Inhibition of CYP2D6 and CYP3A4. Antimicrobial Agents and Chemotherapy, 2011, 55, 1063-1067.	3.2	30
228	Intravenous Lipid Emulsion Only Minimally Influences Bupivacaine and Mepivacaine Distribution in Plasma and Does Not Enhance Recovery from Intoxication in Pigs. Anesthesia and Analgesia, 2012, 114, 901-906.	2.2	30
229	Effect of Timing and Route of Methylprednisolone Administration During Pediatric Cardiac Surgical Procedures. Annals of Thoracic Surgery, 2015, 99, 180-185.	1.3	30
230	Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. European Journal of Clinical Pharmacology, 2015, 71, 321-327.	1.9	30
231	Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. Drug Metabolism and Disposition, 2016, 44, 1364-1371.	3.3	30
232	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 83-95.	3.3	30
233	Pharmacokinetics of intravenously administered bumetanide in man. Journal of Pharmacokinetics and Pharmacodynamics, 1980, 8, 219-228.	0.6	29
234	Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and Genomics, 2008, 18, 921-926.	1.5	29

#	ARTICLE	IF	CITATIONS
235	Adsorption of Sulfonylureas onto Activated Charcoal In Vitro. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 253-256.	3.3	28
236	Effect of Delayed Administration of Activated Charcoal on the Absorption of Conventional and Slow-Release Verapamil. <i>Journal of Toxicology: Clinical Toxicology</i> , 1997, 35, 263-268.	1.5	28
237	Pharmacokinetics of Ropivacaine in Patients with Chronic End-stage Liver Disease. <i>Anesthesiology</i> , 2007, 106, 43-55.	2.5	27
238	No Antidotal Effect of Intravenous Lipid Emulsion in Experimental Amitriptyline Intoxication Despite Significant Entrapment of Amitriptyline. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 378-383.	2.5	27
239	S-ketamine concentrations are greatly increased by grapefruit juice. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 979-986.	1.9	26
240	Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 255-260.	4.7	25
241	Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 653-657.	1.9	25
242	Rifampicin markedly decreases the exposure to oral and intravenous tramadol. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1293-1301.	1.9	25
243	Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1655-1660.	3.3	25
244	Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug-Drug Interaction. <i>Clinical and Translational Science</i> , 2020, 13, 345-351.	3.1	25
245	Lack of Effect of Antimycotic Itraconazole on the Pharmacokinetics or Pharmacodynamics of Temazepam. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 124-127.	2.0	25
246	The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 645-651.	1.9	24
247	Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 497-502.	1.9	24
248	Effect of Clarithromycin and Itraconazole on the Pharmacokinetics of Ropivacaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2001, 88, 187-191.	0.0	24
249	Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 344-350.	4.7	23
250	Effect of voriconazole on the pharmacokinetics of diclofenac. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 651-656.	1.9	23
251	Intravenous Oxycodone for Pain Relief in the First Stage of Labour — Maternal Pharmacokinetics and Neonatal Exposure. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 182-188.	2.5	23
252	Withdrawal from long-term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 330-340.	2.5	23

#	ARTICLE	IF	CITATIONS
253	Interaction between Erythromycin and the Benzodiazepines Diazepam and Flunitrazepam. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 78, 117-122.	0.0	22
254	Effect of Caffeine-Containing versus Decaffeinated Coffee on Serum Clozapine Concentrations in Hospitalised Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 94, 13-18.	2.5	22
255	Sotalol Intoxication, Two Patients with Concentration -Effect Relationships. <i>Acta Pharmacologica Et Toxicologica</i> , 1979, 45, 52-57.	0.0	22
256	Increased incidence of Merkel cell carcinoma among younger statin users. <i>Cancer Epidemiology</i> , 2012, 36, 421-424.	1.9	22
257	Drug-Related Inadvertent Deaths in a University Hospital - A Declining Trend. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 421-426.	2.5	22
258	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2018, 46, 141-150.	3.3	22
259	CYP3A4 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 448-457.	4.7	22
260	Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 29-33.	2.4	22
261	Bumetanide kinetics in renal failure. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 582-588.	4.7	21
262	Pharmacokinetics of verapamil in overdose. <i>Human and Experimental Toxicology</i> , 1997, 16, 35-37.	2.2	21
263	Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 116-120.	2.4	21
264	The Analgesic Concentration of Oxycodone with Co-administration of Paracetamol - A Dose-Finding Study in Adult Patients Undergoing Laparoscopic Cholecystectomy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 391-395.	2.5	21
265	Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1378-1385.	1.3	21
266	Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 25-31.	4.7	20
267	Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. <i>BMC Geriatrics</i> , 2014, 14, 121.	2.7	20
268	Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer - Which Factors Matter?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 653-662.	4.7	20
269	Effect of Albumin and Cytosol on Enzyme Kinetics of Tolbutamide Hydroxylation and on Inhibition of CYP2C9 by Gemfibrozil in Human Liver Microsomes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 43-49.	2.5	19
270	The Effect of Erythromycin, Fluvoxamine, and Their Combination on the Pharmacokinetics of Ropivacaine. <i>Anesthesia and Analgesia</i> , 2000, 91, 1207-1212.	2.2	18

#	ARTICLE	IF	CITATIONS
271	Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 399-407.	2.4	18
272	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 484-492.	4.7	18
273	Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition. <i>Microbiome</i> , 2020, 8, 121.	11.1	18
274	Pharmacokinetics of antiepileptic drugs. <i>Acta Neurologica Scandinavica</i> , 1983, 68, 17-27.	2.1	17
275	Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between Ketamine and Ticlopidine in Healthy Human Volunteers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 687-697.	2.5	17
276	Severe Poisoning in a Child Caused by a Small Dose of Clonidine. <i>Clinical Toxicology</i> , 1979, 14, 369-374.	0.5	16
277	Enhancement of absorption and effect of glipizide by magnesium hydroxide. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 49, 39-43.	4.7	16
278	Lack of Interaction of Erythromycin with Temazepam. <i>Therapeutic Drug Monitoring</i> , 1994, 16, 548-551.	2.0	16
279	Effect of Rifampicin on the Pharmacokinetics of Atenolol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 555-558.	2.5	16
280	Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 511-519.	1.9	16
281	Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 89-95.	1.9	16
282	Effect of Activated Charcoal on the Absorption of Amiodarone. <i>Human and Experimental Toxicology</i> , 1991, 10, 327-329.	2.2	15
283	The Effect of Activated Charcoal on the Absorption of Fluoxetine, with Special Reference to Delayed Charcoal Administration. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1996, 79, 270-273.	0.0	15
284	Effect of Time Interval between Food and Drug Ingestion on the Absorption of Oxybutynin from a Controlled-Release Tablet. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1997, 81, 31-34.	0.0	15
285	Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 867-875.	1.9	15
286	Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1363-1371.	1.9	15
287	Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. <i>Drug Metabolism and Disposition</i> , 2019, 47, 377-385.	3.3	15
288	Capacity of Two Forms of Activated Charcoal to Adsorb Nefopam In Vitro and to Reduce its Toxicity In Vivo. <i>Journal of Toxicology: Clinical Toxicology</i> , 1983, 21, 333-342.	1.5	14

#	ARTICLE	IF	CITATIONS
289	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 495-504.	4.7	14
290	Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1982, 7, 269-276.	1.6	13
291	The Effect of Erythromycin, Fluvoxamine, and Their Combination on the Pharmacokinetics of Ropivacaine. <i>Anesthesia and Analgesia</i> , 2000, 91, 1207-1212.	2.2	13
292	Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 829-836.	1.9	13
293	Interaction of oxycodone and voriconazole—a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 863-864.	1.9	13
294	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 681-688.	1.9	13
295	Effect of grapefruit juice on the bioactivation of prasugrel. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 139-145.	2.4	13
296	High-Dose Methylprednisolone Has No Benefit Over Moderate Dose for the Correction of Tetralogy of Fallot. <i>Annals of Thoracic Surgery</i> , 2016, 102, 870-876.	1.3	13
297	The Effect of Activated Charcoal on the Absorption and Elimination of Astemizole. <i>Human and Experimental Toxicology</i> , 1994, 13, 502-505.	2.2	12
298	Effect of Itraconazole on the Pharmacokinetics of Inhaled Lidocaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 95, 120-123.	0.0	12
299	Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient mice. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 92, 283-290.	2.9	12
300	The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 151-155.	1.9	12
301	Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 341-345.	2.5	12
302	Voriconazole greatly increases the exposure to oral buprenorphine. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1615-1622.	1.9	12
303	Effect of Activated Charcoal on the Pharmacokinetics of Pholcodine, with Special Reference to Delayed Charcoal Ingestion. <i>Therapeutic Drug Monitoring</i> , 1997, 19, 46-50.	2.0	12
304	Reversible Adsorption of Nicotinic Acid onto Charcoal In Vitro. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 917-919.	3.3	11
305	Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 29-33.	2.4	11
306	Effect of Itraconazole on the Pharmacokinetics of Atenolol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 97, 395-398.	2.5	11

#	ARTICLE	IF	CITATIONS
307	Effect of Fluvoxamine and Erythromycin on the Pharmacokinetics of Oral Lidocaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 168-172.	2.5	11
308	Interaction between Erythromycin and Nitrazepam in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1995, 76, 255-258.	0.0	10
309	Lack of Effect of Terfenadine on the Pharmacokinetics of the CYP3A4 Substrate Buspirone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 84, 165-169.	0.0	9
310	In vitro and in vivo entrapment of bupivacaine by lipid dispersions. <i>Journal of Chromatography A</i> , 2012, 1254, 125-131.	3.7	9
311	Towards Safer and More Predictable Drug Treatment – Reflections from Studies of the First <sc>BCPT</sc> Prize Awardee. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 207-218.	2.5	9
312	Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2068-2076.	3.3	9
313	Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00271.	2.4	9
314	Effect of Phenytoin on Serum Lipoproteins in Middle-Aged Men. <i>Journal of Cardiovascular Pharmacology</i> , 1981, 3, 207-214.	1.9	8
315	Effect of Total Drug Concentration on the Free Fraction in Uremic Sera. <i>Therapeutic Drug Monitoring</i> , 1986, 8, 27-31.	2.0	8
316	Failure of Oral Activated Charcoal to Accelerate the Elimination of Amiodarone and Chloroquine. <i>Human and Experimental Toxicology</i> , 1992, 11, 491-494.	2.2	8
317	Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 865-870.	1.9	7
318	Determination of Buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in Human Plasma by Capillary Gas Chromatography. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 317.	2.0	7
319	The Effect of pH on the In-vitro Dissolution of Three Second-generation Sulphonylurea Preparations: Mechanism of Antacid-sulphonylurea Interaction. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 899-901.	2.4	6
320	No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1159-1167.	1.9	6
321	Lipid Rescue – Efficacy and Safety Still Unproven. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 345-348.	2.5	6
322	Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. <i>Canadian Journal of Anaesthesia</i> , 1997, 44, 1269-1274.	1.6	5
323	Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study. <i>BMC Geriatrics</i> , 2018, 18, 142.	2.7	5
324	Therapeutic Cyclosporine Monitoring. <i>Therapeutic Drug Monitoring</i> , 1990, 12, 353-358.	2.0	4

#	ARTICLE	IF	CITATIONS
325	Can barbiturate anaesthesia cure infantile spasms?. Brain and Development, 1988, 10, 300-304.	1.1	2
326	Re: Pergolizzi et al. 2011: Exposure to potential CYP450 pharmacokinetic drug-drug interactions. Pain Practice, 2012, 12, 81-82.	1.9	1
327	Infections and possible vaccine-drug interactions. European Journal of Clinical Pharmacology, 2014, 70, 889-890.	1.9	1
328	The role of concentration-effect relationships in the QTc interval prolongation: case sotalol. British Journal of Clinical Pharmacology, 2015, 79, 1040-1041.	2.4	1
329	Response to "Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?". Clinical Pharmacology and Therapeutics, 2019, 105, 322-322.	4.7	1
330	Lifetime antimicrobial use is associated with weight status in early adolescence: A register-based cohort study. Pediatric Obesity, 2021, 16, e12727.	2.8	1
331	Effect of Clarithromycin and Itraconazole on the Pharmacokinetics of Ropivacaine. Basic and Clinical Pharmacology and Toxicology, 2008, 88, 187-191.	0.0	0
332	Postoperative oxycodone in breast cancer surgery: What factors associate with analgesic plasma concentrations?. Scandinavian Journal of Pain, 2016, 12, 118-119.	1.3	0
333	Sotalol, unlike the other beta-blockers, increases the QT _c interval and risk of torsades de pointes ventricular tachycardia in severe poisonings. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 487-488.	2.5	0
334	Plasma Clearance of Fentanyl in Relation To Gestational Age and Birth Weight. Pediatric Research, 1999, 45, 901-901.	2.3	0